November 2008 in “British Journal of Hospital Medicine” Non-drug methods effectively managed agitation in a patient with a heart device, leading to improved mental function.
January 2023 in “Mansoura Medical Journal” Higher ischemia-modified albumin levels are linked to acne severity.
101 citations
,
August 2008 in “Mayo Clinic Proceedings” PAD is common but often missed, needing lifestyle changes and medication for better outcomes.
31 citations
,
July 2012 in “Journal of Lipid Research” ACBP is crucial for healthy skin in mice.
July 2024 in “Periodontology 2000” Autologous platelet concentrates show promise in esthetic treatments but need more standardized research.
2 citations
,
January 2023 in “Skin Appendage Disorders” Beard alopecia areata causes patchy beard hair loss, often treatable with janus kinase inhibitors.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
25 citations
,
October 2018 in “Journal of Mind and Medical Sciences” New oral anticoagulants are safer and easier to use with new reversal agents for bleeding emergencies.
June 1985 in “Journal of the American Academy of Dermatology”
October 2025 in “Electronic Theses and Dissertations Repository (University of Pisa)” Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.
July 2011 in “Facial Plastic Surgery” The document provides a quiz for physicians to earn continuing medical education credits in facial plastic surgery.
6 citations
,
May 2021 in “Journal of Health Sciences” Intravenous delivery of autologous activated platelet-rich plasma is safe.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
July 2010 in “Hair transplant forum international” The ABHRS held a test in Capri, Italy.
Baricitinib shows promise for treating alopecia areata with mild side effects.
9 citations
,
January 1999 in “Dermatology” Acyclovir can prevent rejection of skin grafts in herpes-related lip leucoderma.
February 2025 in “Canadian Journal of Health Technologies” Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
1 citations
,
July 2020 in “Acta Neuropsychologica” Valproic acid effectively reduces aggressive and impulsive behaviors in brain injury patients with acceptable side effects.
March 2026 in “Journal of the European Academy of Dermatology and Venereology” VESALT improves alopecia areata assessment by including non-scalp areas and is reliable and user-friendly.
2 citations
,
April 2023 in “Expert Review of Clinical Immunology” Baricitinib is effective as a treatment for severe hair loss.
28 citations
,
August 1981 in “Journal of the American Academy of Dermatology” Retinoic acid is effective for treating eruptive vellus hair cysts.
7 citations
,
April 2021 in “Journal of The American Academy of Dermatology” A new teledermatology system improved access and reduced wait times for skin care.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
1 citations
,
March 2025 in “Skin Appendage Disorders” Baricitinib for alopecia areata may rarely cause eye issues like keratitis.
May 2024 in “European Journal of Immunology” Vitamin B5 and coenzyme A may help regulate the immune system and could improve treatments for chronic diseases and cancer.
April 2019 in “International research journal of pharmacy” Adiantum capillus extract reduces pain and swelling in animals.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.